Pharmaceutical

FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease

J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.

Mar 21, 2025 - 06:00
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
J&J has received US FDA approval for Tremfya (guselkumab), to treat moderately to severely active Crohn's disease (CD) in adults.
Read the original article

Tags:

Previous Article

Narrow Field Imager from NRL Debuts on NASA’s PUNCH Mission

Next Article

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

argenx’s VYVDURA gains approval in Japan for gMG treatment

argenx’s VYVDURA gains approval in Japan for gMG treatment

Jan 19, 2024

STAT+: Texas taxpayers wanted to help the poor get health care. Instead, they’re funding a medical school at a wealthy university

STAT+: Texas taxpayers wanted to help the poor get heal...

Jan 2, 2024

Dizal receives approval in China for NSCLC therapy

Dizal receives approval in China for NSCLC therapy

Aug 24, 2023